The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•11 February 2026•

1 min read

Candriam Trims Labcorp Stake by 39.3% Amidst Mixed Analyst Sentiment

A man in a suit over a stock chart with 'Mondelez International' text, surrounded by chocolate, cocoa beans, factories, and shops.

Candriam S.C.A. significantly reduced its holdings in Labcorp Holdings Inc. during the third quarter, cutting its stake by 39.3%. The investment firm now holds 46,666 shares of Labcorp, valued at approximately $13.4 million. Despite this reduction by an institutional investor, financial analysts maintain a "Moderate Buy" consensus for Labcorp. The stock holds an average price target of $300.75, bolstered by recent upgrades from firms like JPMorgan and Mizuho. Furthermore, Labcorp recently declared a quarterly dividend of $0.72 per share, indicating a 1.0% yield. This combination of institutional selling and positive analyst outlook, alongside a dividend declaration, presents a mixed picture for the diagnostic services provider.